MA37569B1 - Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc - Google Patents

Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Info

Publication number
MA37569B1
MA37569B1 MA37569A MA37569A MA37569B1 MA 37569 B1 MA37569 B1 MA 37569B1 MA 37569 A MA37569 A MA 37569A MA 37569 A MA37569 A MA 37569A MA 37569 B1 MA37569 B1 MA 37569B1
Authority
MA
Morocco
Prior art keywords
gcc
antibody molecules
relates
methods
immunoconjugates
Prior art date
Application number
MA37569A
Other languages
English (en)
Inventor
Helen Frank
Alice Mcdonald
Theresa O'keefe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37569(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA37569B1 publication Critical patent/MA37569B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps et des fragments liant les antigènes d'anticorps liant la gcc. L'invention concerne également des méthodes de diagnostic permettant d'identifier des patients qui devraient recevoir une thérapie ciblée sur la gcc utilisant les anticorps anti-gcc de la présente invention. Les molécules d'anticorps anti-gcc peuvent être utilisées en tant que molécules d'anticorps nus et en tant que composants d'immunoconjugués. En conséquence, selon un autre aspect, l'invention concerne des immunoconjugués comprenant une molécule d'anticorps anti-gcc selon la présente invention et un agent thérapeutique ou un marqueur. L'invention concerne également des méthodes d'utilisation des molécules d'anticorps anti-gcc et des immunoconjugués décrits ici, par exemple en vue de la détection de la gcc et de cellules ou de tissus exprimant la gcc. Lesdites méthodes peuvent être utilisées, entre autres, en vue du diagnostic, du pronostic, de l'imagerie ou de la détermination des stades d'une maladie évolutive à médiation par la gcc. En conséquence, selon certains aspects, l'invention concerne des méthodes d'identification d'un sujet devant faire l'objet d'un traitement par une thérapie ciblée sur la gcc, par exemple une thérapie à base d'anticorps anti-gcc, faisant notamment appel à un immunoconjugué comprenant un anticorps anti-gcc conjugué à un agent thérapeutique.
MA37569A 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc MA37569B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
PCT/US2013/038542 WO2013163633A1 (fr) 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Publications (1)

Publication Number Publication Date
MA37569B1 true MA37569B1 (fr) 2020-08-31

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37569A MA37569B1 (fr) 2012-04-27 2013-04-27 Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc

Country Status (41)

Country Link
US (3) US9000129B2 (fr)
EP (1) EP2841575B1 (fr)
JP (2) JP6472746B2 (fr)
KR (1) KR102046435B1 (fr)
CN (1) CN104395470B (fr)
AR (1) AR090884A1 (fr)
AU (1) AU2013251312B2 (fr)
CA (1) CA2871614C (fr)
CL (1) CL2014002911A1 (fr)
CO (1) CO7280144A2 (fr)
CR (1) CR20140497A (fr)
CY (1) CY1122557T1 (fr)
DK (1) DK2841575T3 (fr)
DO (1) DOP2014000242A (fr)
EA (1) EA034689B1 (fr)
EC (1) ECSP14028523A (fr)
ES (1) ES2749181T3 (fr)
GE (1) GEP201706737B (fr)
HR (1) HRP20191690T1 (fr)
HU (1) HUE046404T2 (fr)
IL (1) IL235307B (fr)
LT (1) LT2841575T (fr)
MA (1) MA37569B1 (fr)
ME (1) ME03560B (fr)
MX (1) MX362020B (fr)
MY (1) MY188442A (fr)
NZ (1) NZ701601A (fr)
PE (1) PE20142322A1 (fr)
PH (1) PH12014502399B1 (fr)
PL (1) PL2841575T3 (fr)
PT (1) PT2841575T (fr)
RS (1) RS59370B1 (fr)
SA (1) SA113340502B1 (fr)
SG (1) SG11201406855TA (fr)
SI (1) SI2841575T1 (fr)
SM (1) SMT201900536T1 (fr)
TN (1) TN2014000454A1 (fr)
TW (1) TWI631137B (fr)
UA (1) UA117910C2 (fr)
WO (1) WO2013163633A1 (fr)
ZA (1) ZA201407723B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774032C (fr) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Molecules d'anticorps anti-gcc, compositions et procedes apparentes
US20160264663A1 (en) * 2013-10-21 2016-09-15 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
WO2015123574A1 (fr) 2014-02-14 2015-08-20 The Board Of Trustees Of The University Of Arkansas Adduits de protéine acétaminophène et leurs procédés d'utilisation
JP6785239B2 (ja) 2014-12-03 2020-11-18 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
CA3000242A1 (fr) 2015-10-01 2017-04-06 The Centre For Drug Research And Development Anticorps anti-podocalyxine et leurs methodes d'utilisation
US11473081B2 (en) 2016-12-12 2022-10-18 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
CN111448569B (zh) * 2017-12-06 2023-09-26 文塔纳医疗系统公司 存储和检索数字病理学分析结果的方法
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
PL3846788T3 (pl) * 2018-09-05 2026-02-23 Universiteit Van Amsterdam Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona
WO2021205325A1 (fr) * 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
WO2022127871A1 (fr) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Molécules de liaison à gucy2c et leurs utilisations
MX2023011862A (es) * 2021-04-07 2024-01-08 Lg Chemical Ltd Polipeptido de union a gucy2c y usos del mismo.
KR20250075590A (ko) * 2022-09-28 2025-05-28 레전드 바이오테크 아일랜드 리미티드 Gcc를 표적으로 하는 항체 및 키메라 항원 수용체 및 이의 사용 방법
KR20250099224A (ko) 2022-11-01 2025-07-01 하이델베르크 파마 리서치 게엠베하 항-gucy2c 항체 및 이의 용도
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
WO2025061149A1 (fr) * 2023-09-21 2025-03-27 南京传奇生物科技有限公司 Anticorps anti-gcc, récepteur antigénique chimérique et utilisation
EP4566631A1 (fr) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH Nouveau conjugué anticorps-médicament et ses procédés de production et d'utilisation
CN120965861B (zh) * 2025-10-22 2026-02-13 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
ATE259648T1 (de) 1993-10-26 2004-03-15 Univ Jefferson Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
CA2254082C (fr) 1996-05-03 2012-09-11 Thomas Jefferson University Vaccin contre le cancer recto-colique metastatique
US6602659B1 (en) 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ATE452989T1 (de) 2000-03-27 2010-01-15 Univ Jefferson Zusammensetzungen und methoden zur identifizierung von krebszellen
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002072600A2 (fr) 2001-01-26 2002-09-19 Inhibitex, Inc. Anticorps monoclonaux contre la proteine clfa et procede d'utilisation dans le traitement et la prevention d'infections
DE60233040D1 (de) 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004071436A2 (fr) 2003-02-10 2004-08-26 Thomas Jefferson University Utilisation de ligands gcc
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1781339B1 (fr) 2004-06-25 2013-12-25 Thomas Jefferson University Ligands de la Guanylyle cyclase C
WO2006068953A2 (fr) 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
KR101588276B1 (ko) * 2007-08-10 2016-01-26 센토코 오르토 바이오테크 인코포레이티드 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물
KR101709488B1 (ko) 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
AU2008334070B2 (en) * 2007-11-30 2015-04-16 Genentech, Inc. VEGF polymorphisms and anti-angiogenesis therapy
US20110195415A1 (en) 2008-05-13 2011-08-11 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
DK2881402T3 (en) * 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
US20110306055A1 (en) 2009-02-25 2011-12-15 Diagnocure Inc. Method for Detecting Metastasis of GI Cancer
JPWO2010104035A1 (ja) * 2009-03-12 2012-09-13 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CA2801729A1 (fr) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions et procedes d'activation de la guanylyl cyclase c
JP5955771B2 (ja) 2009-10-22 2016-07-20 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法
CA2774032C (fr) * 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Molecules d'anticorps anti-gcc, compositions et procedes apparentes
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
JP2013539460A (ja) * 2010-08-13 2013-10-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用療法のためのバイオマーカーとしてのニューロピリン
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150122730A (ko) * 2013-02-28 2015-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 암의 치료에서 항-gcc 항체-약물 콘주게이트 및 dna 손상 제제의 투여

Also Published As

Publication number Publication date
EP2841575A1 (fr) 2015-03-04
IL235307A0 (en) 2014-12-31
US9273146B1 (en) 2016-03-01
LT2841575T (lt) 2019-10-10
IL235307B (en) 2019-07-31
HUE046404T2 (hu) 2020-02-28
MX2014013081A (es) 2015-01-12
TWI631137B (zh) 2018-08-01
RS59370B1 (sr) 2019-11-29
CN104395470B (zh) 2018-02-06
CN104395470A (zh) 2015-03-04
KR102046435B1 (ko) 2019-11-19
MX362020B (es) 2019-01-04
TN2014000454A1 (en) 2016-03-30
KR20150004882A (ko) 2015-01-13
CA2871614C (fr) 2021-08-31
DK2841575T3 (da) 2019-09-23
JP2015516985A (ja) 2015-06-18
CR20140497A (es) 2015-02-10
EA201491977A1 (ru) 2015-04-30
TW201348258A (zh) 2013-12-01
ECSP14028523A (es) 2015-09-30
US20130287783A1 (en) 2013-10-31
UA117910C2 (uk) 2018-10-25
SA113340502B1 (ar) 2015-09-17
DOP2014000242A (es) 2014-11-30
JP6517267B2 (ja) 2019-05-22
AU2013251312A1 (en) 2014-10-30
CA2871614A1 (fr) 2013-10-31
PE20142322A1 (es) 2015-01-25
ME03560B (fr) 2020-07-20
CL2014002911A1 (es) 2015-01-30
BR112014026742A2 (pt) 2017-07-11
AU2013251312B2 (en) 2018-03-22
PL2841575T3 (pl) 2020-01-31
CO7280144A2 (es) 2015-05-29
JP6472746B2 (ja) 2019-02-20
WO2013163633A1 (fr) 2013-10-31
NZ701601A (en) 2016-09-30
EA034689B1 (ru) 2020-03-06
PH12014502399B1 (en) 2022-04-22
EP2841575B1 (fr) 2019-06-26
EP2841575A4 (fr) 2016-06-15
HRP20191690T1 (hr) 2019-12-27
HK1208049A1 (en) 2016-02-19
SMT201900536T1 (it) 2019-11-13
MY188442A (en) 2021-12-09
PT2841575T (pt) 2019-10-11
PH12014502399A1 (en) 2014-12-22
SI2841575T1 (sl) 2019-11-29
JP2017131245A (ja) 2017-08-03
SG11201406855TA (en) 2014-11-27
AR090884A1 (es) 2014-12-10
US9000129B2 (en) 2015-04-07
GEP201706737B (en) 2017-09-25
CY1122557T1 (el) 2021-01-27
ES2749181T3 (es) 2020-03-19
ZA201407723B (en) 2019-01-30
US20160130344A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
MA37569B1 (fr) Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc
Pisa et al. Parkinson's disease: a comprehensive analysis of fungi and bacteria in brain tissue
WO2009085216A3 (fr) Compositions et méthodes de détection ou d'élimination de cellules sénescentes pour le diagnostic ou le traitement de maladies
Dykman et al. Multifunctional gold-based nanocomposites for theranostics
Beer et al. Analysis of the secretome of apoptotic peripheral blood mononuclear cells: impact of released proteins and exosomes for tissue regeneration
MA43459A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
EP2117604A4 (fr) Procédés et compositions pour un marquage par f-18 amélioré de protéines, peptides et autres molécules
WO2008103645A3 (fr) Antigènes spécifiques du cancer de la prostate et du mélanome
Moore et al. A Photoacoustic‐Fluorescent Imaging Probe for Proteolytic Gingipains Expressed by Porphyromonas gingivalis
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
MX2015008448A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos.
Libner et al. Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis
Dahis et al. Monitoring melanoma responses to sting agonism and focused ultrasound thermal ablation using microneedles and ultrasensitive single molecule arrays
Ferguson et al. Using magnetic resonance imaging to evaluate dendritic cell-based vaccination
Kim et al. In Situ Detection of HY-Specific T Cells in Acute Graft-versus-Host Disease–Affected Male Skin after Sex-Mismatched Stem Cell Transplantation
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
WO2018039810A1 (fr) Fourniture d'un produit cellulaire thérapeutiquement actif
Lund et al. Association of MBP peptides with Hsp70 in normal appearing human white matter
Larenkov et al. Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development
Koob New dimensions in human laboratory models of addiction.
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
Lajolo et al. Blandin-nuhn gland mucocele: presentation of a new case and review of the literature
Kwon et al. Bean Extract-Based Gargle as Promising Tool for Efficient Diagnosis of COVID-19 at Early Stage Using Rapid Antigen Tests: A Clinical, Prospective, Diagnostic Sensitivity Study